Foley Hoag LLP recently advised clinical-stage pharmaceutical company Calithera Biosciences, Inc. as it entered into a worldwide license agreement with TransTech Pharma, granting Calithera exclusive rights to research, develop and commercialize TransTech's portfolio of hexokinase II inhibitors. Hexokinase II is the first and rate-limiting enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks that feed cancer cell growth.
Headquartered in South San Francisco, Calithera focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Under the terms of the license agreement, Calithera will obtain exclusive, global rights to TransTech's hexokinase II inhibitors for research, development and commercialization. TransTech will receive an up-front payment and be eligible to receive future development and commercialization milestones, as well as royalties on sales of approved products.
Foley Hoag attorneys Hemmie Chang, David Halstead and Karen Tepichin advised Calithera on this agreement.